Ind-Swift surges on talk of atorvastatin API supply deal with Ranbaxy
This article was originally published in Scrip
Executive Summary
Shares of Ind-Swift Laboratories were on a roll on Indian bourses on 14 September following reports that the firm was in discussions to supply atorvastatin active pharmaceutical ingredient (API) to Ranbaxy for the latter's cut-price generic version of Pfizer's Lipitor. A US launch of Ranbaxy's product is expected at the end of November this year.
You may also be interested in...
India-China Tango: Can Gland Sustain Listing Luster?
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A Peek At How Janssen’s Supply Chain Withstood COVID-19 Disruptions
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
The Golden Winged Warbler And Creating Pharma Supply Chain Immunity
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Need a specific report? 1000+ reports available
Buy Reports